Alle verbonden artikelen

A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes.

Auteurs : Garaud S, Gu-Trantien C, Lodewyckx JN, Boisson A, De Silva P, Buisseret L, Migliori E, Libin M, Naveaux C, Duvillier H, Willard-Gallo K
Jaar : 2014
Journal : J Vis Exp
Volume : null(94)

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Auteurs : Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart-Gebhart M, Sotiriou C, Ignatiadis M
Jaar : 2014
Journal : Ann Oncol
Volume : 25(10)
Pagina's : 1959-65

Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

Auteurs : Criscitiello C, Azim HA, de Azambuja E, Rubio IT
Jaar : 2014
Journal : Ann Oncol
Volume : 25(4)
Pagina's : 910-1

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

Auteurs : McCullough AE, + collaborators (among others :, Piccart-Gebhart M, Viale G
Jaar : 2014
Journal : Breast Cancer Res. Treat.
Volume : 143(3)
Pagina's : 485-92

Fertility issues in young breast cancer patients: what women want.

Auteurs : Lambertini M, Pinto AC, Del Mastro L
Jaar : 2014
Journal : J Thorac Dis
Volume : 6(6)
Pagina's : 584-8

Anticancer drug development: moving away from the old habits.

Auteurs : Ades F, Zardavas D, Aftimos P, Awada A
Jaar : 2014
Journal : Curr Opin Oncol
Volume : 26(3)
Pagina's : 334-9

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.

Auteurs : Viale G, Slaets L, Bogaerts J, Rutgers E, + collaborators (among others :, Piccart-Gebhart M, Cardoso F
Jaar : 2014
Journal : Ann Oncol
Volume : 25(4)
Pagina's : 816-23

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Auteurs : Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A
Jaar : 2014
Journal : Breast Cancer Res. Treat.
Volume : 148(3)
Pagina's : 553-61

Breast cancer control in China: challenges and opportunities of the use of population-based routine data studies.

Auteurs : Pinto AC, Canário R, Fidalgo P
Jaar : 2014
Journal : J Thorac Dis
Volume : 6(9)
Pagina's : 1167-9

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).

Auteurs : Awada A, Bondarenko IN, Bonneterre J, Nowara E, Ferrero JM, Bakshi AV, Wilke C, Piccart-Gebhart M
Jaar : 2014
Journal : Ann Oncol
Volume : 25(4)
Pagina's : 824-31

Belgian Society of Medical oncology (BSMO - task force on breast cancer survivorship)

Auteurs : de Azambuja E, Azim HA, Buisseret L, Langenaeken C, Tkint de Roodenbeke D
Jaar : 2014
Journal : Belgian J Medical Oncology
Volume : 7(5)
Pagina's : 142-155

Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.

Auteurs : Krayem M, Journe F, Wiedig M, Morandini R, Sales F, Awada A, Ghanem G
Jaar : 2014
Journal : Eur. J. Cancer
Volume : 50(7)
Pagina's : 1310-20

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

Auteurs : Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart-Gebhart M, Rugo H, Sledge G, Thomssen C, + collaborators (among others :, Winer A
Jaar : 2014
Journal : Breast
Volume : 23(5)
Pagina's : 489-502

What is your diagnosis ?

Auteurs : de Azambuja E
Jaar : 2014
Journal : Belgian J Medical Oncology
Volume : 8(1)
Pagina's : 21-22

Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?

Auteurs : Ignatiadis M, Dawson SJ
Jaar : 2014
Journal : Ann Oncol
Volume : 25(12)
Pagina's : 2304-2313

The landscape of medical oncology in Europe by 2020.

Auteurs : de Azambuja E, Ameye L, Paesmans M, Zielinski CC, Piccart-Gebhart M, Preusser M
Jaar : 2014
Journal : Ann Oncol
Volume : 25(2)
Pagina's : 525-8

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

Auteurs : Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart-Gebhart M, Rugo H, Sledge G, Thomssen C
Jaar : 2014
Journal : Ann Oncol
Volume : 25(10)
Pagina's : 1871-88

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

Auteurs : Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, Van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S
Jaar : 2014
Journal : Lancet Oncol
Volume : 15(4)
Pagina's : 406-14

Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine.

Auteurs : Aftimos P, Barthelemy P, Awada A
Jaar : 2014
Journal : Discov Med
Volume : 17(92)
Pagina's : 81-91

Words matter: distinguishing personalized medicine" and "biologically personalized therapeutics"."

Auteurs : Cherny NI, de Vries EG, Emanuel L, Fallowfield L, Francis PA, Gabizon A, Piccart-Gebhart M, Sidransky D, Soussan-Gutman L, Tziraki C
Jaar : 2014
Journal : J. Natl. Cancer Inst.
Volume : 106(12)